![Philip L'Huillier](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Philip L'Huillier
Chief Executive Officer at
SCANCELL HOLDINGS PLC
Profile
Philip John L'Huillier is Chief Executive Officer & Director at Scancell Holdings Plc since 2024.
Former roles include Chief Executive Officer & Chief Scientific Officer at ProBio, Inc., Chief Executive Officer & Managing Director at CatalYm GmbH from 2021 to 2024, Director & Director-Business Management at Cancer Research Technology Ltd., Non-Executive Director at Hybrid BioSystems Ltd. from 2009 to 2010, Non-Executive Director at Akamis Bio Ltd., Director at BliNK Therapeutics Ltd., Non-Executive Director at Artios Pharma Ltd., Director at Achilles Therapeutics Plc, Principal at CRT Group Plc, and Principal at Biofocus Discovery Ltd. Education includes a doctorate from Auckland University.
Philip L'Huillier active positions
| Companies | Position | Start |
|---|---|---|
| SCANCELL HOLDINGS PLC | Chief Executive Officer | 17/11/2024 |
Former positions of Philip L'Huillier
| Companies | Position | End |
|---|---|---|
CatalYm GmbH
 CatalYm GmbH Pharmaceuticals: MajorHealth Technology Specializes in catalyzing immunotherapy | Chief Executive Officer | 10/10/2024 |
Hybrid BioSystems Ltd.
 Hybrid BioSystems Ltd. Miscellaneous Commercial ServicesCommercial Services Develops gene therapy treatments for ovarian and prostate cancer | Director/Board Member | 14/12/2010 |
| ACHILLES THERAPEUTICS PLC | Director/Board Member | - |
Artios Pharma Ltd.
 Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products for cancer treatment | Director/Board Member | - |
BliNK Therapeutics Ltd.
 BliNK Therapeutics Ltd. BiotechnologyHealth Technology Produces therapeutic monoclonal antibodies | Director/Board Member | - |
Training of Philip L'Huillier
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
2
1st degree connections
12
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 12 |
|---|---|
CRT Group Plc | |
ProBio, Inc.
 ProBio, Inc. Miscellaneous Commercial ServicesCommercial Services Provides advanced animal reproductive, modification, and associated technologies for use in agriculture and medicine | Commercial Services |
Auckland University
 Auckland University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cancer Research Technology Ltd.
 Cancer Research Technology Ltd. Medical SpecialtiesHealth Technology Develops cancer therapeutics, vaccines, and diagnostics | Health Technology |
Hybrid BioSystems Ltd.
Hybrid BioSystems Ltd. Miscellaneous Commercial ServicesCommercial Services Develops gene therapy treatments for ovarian and prostate cancer | Commercial Services |
Scancell Holdings Plc
 Scancell Holdings Plc BiotechnologyHealth Technology Develops therapeutic cancer vaccines | Health Technology |
Biofocus Discovery Ltd. | |
Akamis Bio Ltd.
 Akamis Bio Ltd. BiotechnologyHealth Technology Operates as a clinical-stage oncology company that engages in development of tumor gene therapies | Health Technology |
BliNK Therapeutics Ltd.
BliNK Therapeutics Ltd. BiotechnologyHealth Technology Produces therapeutic monoclonal antibodies | Health Technology |
Artios Pharma Ltd.
Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products for cancer treatment | Health Technology |
CatalYm GmbH
CatalYm GmbH Pharmaceuticals: MajorHealth Technology Specializes in catalyzing immunotherapy | Health Technology |
Achilles Therapeutics Plc
 Achilles Therapeutics Plc Pharmaceuticals: MajorHealth Technology Develops and sells cancer immunotherapies | Health Technology |
- Stock Market
- Insiders
- Philip L'Huillier
Choose MarketScreener 
